Expanding the PROTACtable Genome Universe of E3 Ligases
Proteolysis-targeting chimera (PROTAC) and other targeted protein degradation (TPD) molecules are transforming the landscape of drug discovery. These innovative compounds leverage the ubiquitin-proteasome system (UPS) to degrade challenging targets, providing new avenues for intervention beyond traditional small molecules. However, the power of PROTACs lies in the engagement of E3 ligases, and currently, less than two percent of the vast array of E3 ligases in the human genome have been explored in the TPD field.
Dr. Yuan Liu from Indiana University will be joining Technology Networks to provide a comprehensive overview of this promising field, and how it is paving the way for potential therapeutics.
Attend this webinar to:
- Gain insights into the mechanism and significance of PROTAC in TPD
- Explore the fundamental role played by E3 ligase in PROTAC degradation process
- Recognize the limited exploration of E3 ligases in current studies and the potential for therapeutic possibility
- Discover to how to systematically identify novel E3 ligases